Post-marketing Surveillance of DC Bead in Patients With Hepatocellular Carcinoma
This surveillance's objectives are:

1. Unknown adverse reactions
2. Incidences of adverse drug reaction
3. Factors considered to have effect to safety and effectiveness
Hepatocellular Carcinoma
DEVICE: E7040
Safety and Tolerability as measured by Adverse Events, Up to 30 days
Efficacy of DC bead as assessed by embolic performance, Up to 30 days
This surveillance's objectives are:

1. Unknown adverse reactions
2. Incidences of adverse drug reaction
3. Factors considered to have effect to safety and effectiveness